Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Small cell carcinoma esophagus: A rare entity.

Created on 14 Jul 2026

Authors

Sibgha Aimon, Muhammad Adeel Ahmed, Faisal Ali, Hadi Khan, Muslim Attiq, Hajira Ghairat

Published in

JPMA. The Journal of the Pakistan Medical Association. Volume 76. Issue 7. Pages 1154-1157.

Abstract

Small cell carcinoma of esophagus (SCCE), uncommon and aggressive malignancy with a poor prognosis and limited therapeutic consensus, less than 1% of all oesophageal cancers, presents with symptoms of dysphagia and weight loss, leading to diagnosis through endoscopy and histopathological evaluation. This paper presents two case reports of SCCE. Case 1 involves a 70-year-old male with progressive dysphagia, revealing a lobulated mass in mid-esophagus diagnosed as SCCE. Imaging and biopsy confirmed the diagnosis, with positive markers for CAM5.2 and Chromogranin, managed through a multidisciplinary approach, with chemoradiotherapy initiated as primary treatment due to disease's aggressiveness and limited surgical benefit. Case 2 describes a 60-year-old male with multiple comorbidities, demonstrated rapid disease progression and systemic complications associated with SCCE. Current literature supports the use of chemoradiotherapy for locally advanced SCCE, although overall prognosis remains poor, an average survival of approximately 12 months. Further studies are warranted to establish optimal management strategies.

PMID:
42444230
Bibliographic data and abstract were imported from PubMed on 14 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement